title: Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults.
abstract: This document presents the evidence-based guidelines of the Swedish Society of Infectious Diseases for the management of adult immunocompetent patients with community-acquired pneumonia (CAP), who are assessed at hospital. The prognostic score 'CURB-65' is recommended for all CAP patients in the emergency room. The score provides an assessment tool for the decision regarding outpatient treatment or level of hospital supervision, the choice of microbiological investigations, and empirical antibiotic treatment. In patients with non-severe CAP (CURB-65 score 0-2) we recommend initial narrow-spectrum antibiotic treatment, orally or intravenously, primarily directed at Streptococcus pneumoniae. In those with CURB-65 score 3, penicillin G or a cephalosporin intravenously is recommended. For CURB-65 score 0-3 atypical pathogens should be covered only when they are suspected on clinical or epidemiological grounds. In patients with CURB-65 score 4-5 intravenous combination therapy with either cephalosporin/macrolide or penicillin G/fluoroquinolone is recommended. Efforts should be made to identify the CAP aetiology in order to support the ongoing antibiotic treatment or to suggest treatment alterations. Recommended measures for prevention of CAP include influenza -- and pneumococcal -- vaccination to risk groups and efforts for smoking cessation.
authors.affiliation: Department of Infectious Diseases, Karolinska University Hospital, S-17176 Stockholm, Sweden. jonas.u.hedlund@karolinska.se
authors.forename: Jonas
authors.initials: J
authors.lastname: Hedlund
authors.forename: Kristoffer
authors.initials: K
authors.lastname: Strålin
authors.forename: Ake
authors.initials: A
authors.lastname: Ortqvist
authors.forename: Hans
authors.initials: H
authors.lastname: Holmberg
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001431:Bacteriological Techniques; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D019317:Evidence-Based Medicine; D006801:Humans; D007121:Immunocompetence; D007252:Influenza Vaccines / Q000008:administration & dosage; D022242:Pneumococcal Vaccines / Q000008:administration & dosage; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control; D011018:Pneumonia, Pneumococcal / Q000188:drug therapy; D011379:Prognosis; D013548:Sweden
chemical_list: D000900:Anti-Bacterial Agents; D007252:Influenza Vaccines; D022242:Pneumococcal Vaccines